HEC88473, a novel drug combining GLP-1 and FGF21 receptor activity, lowered blood sugar, reduced triglycerides by up to 43%, and raised adiponectin by up to 91% in its first human trial.
-43% triglyceridesMaximum triglyceride reduction from a single dose of HEC88473 at 62.9 mg in healthy/obese subjects
What the researchers found
HEC88473 is an Fc fusion protein that combines GLP-1 and FGF21 activity in a single molecule. In this phase 1 single-ascending dose trial:
- Pharmacokinetics: The drug splits into two active components after dosing — Fc-GLP-1 (half-life 66.5-119.5 hours) and Fc-FGF21 (half-life 28.4-41.6 hours), with peak levels at 12-14 hours
- Blood sugar: At doses ≥5.1 mg, glucose decreased during oral glucose tolerance tests on days 3 and 7. Maximum reduction was -1.829 mmol/L (placebo-adjusted) at 47.6 mg
- Adiponectin: At doses ≥10.2 mg, levels increased dose-dependently, up to 90.71% from baseline at 62.9 mg
- Triglycerides: At doses ≥17.0 mg, significant dose-dependent reductions up to -43.01% from baseline at 62.9 mg
- Safety: Well tolerated; most adverse events were mild GI disorders
Why it matters
The metabolic drug race is moving beyond single-target approaches. While GLP-1 drugs are effective for blood sugar and weight, adding FGF21 activity could independently improve lipid metabolism and liver health. HEC88473 represents a new strategy: combining an incretin with a metabolic growth factor. The triglyceride and adiponectin effects from a single dose are particularly notable and could be especially relevant for patients with metabolic syndrome or fatty liver disease.
How the study worked
This was a phase 1, single-ascending dose trial (NCT05943886) in healthy and obese Chinese subjects. Participants received single subcutaneous doses of HEC88473 ranging from 0.5 to 62.9 mg or placebo. Researchers measured serum drug concentrations over time (pharmacokinetics), and tracked blood glucose (via oral glucose tolerance test), lipid levels, and adiponectin (pharmacodynamics). Safety was monitored throughout.
What this study cannot tell us
This was a single-dose phase 1 study focused on safety and pharmacokinetics, not efficacy. The sample size was not disclosed in the abstract. Only Chinese subjects were enrolled, so results may not generalize to other populations. No weight loss data was reported (single-dose studies are too short to measure weight effects). The long-term safety and efficacy of repeated dosing remain unknown.
How to read the evidence
This is a phase 1 single-ascending dose trial — the earliest stage of human testing. While it establishes safety and provides preliminary pharmacodynamic signals, it cannot determine clinical efficacy. Much larger and longer trials are needed.
When this study was published
Published in 2025, this represents cutting-edge metabolic drug development. HEC88473 is in the early stages of clinical evaluation, with further trials expected.
The bigger picture
The next frontier in metabolic drug development goes beyond dual GLP-1/GIP agonists like tirzepatide. HEC88473 pairs GLP-1 with FGF21 — a pathway known for its effects on liver fat, lipid metabolism, and insulin sensitivity. Several companies are exploring FGF21-based therapies for MASH (metabolic-associated steatohepatitis), and combining it with GLP-1 could address both weight and liver disease simultaneously.
Questions still open
- Will the impressive single-dose lipid and adiponectin effects translate to meaningful clinical outcomes with repeated dosing?
- Could HEC88473's FGF21 component provide liver fat reduction benefits relevant to MASH treatment?
- How will this GLP-1/FGF21 approach compare to GLP-1/GIP (tirzepatide) or GLP-1/GIP/glucagon (retatrutide) multi-agonists for weight and metabolic outcomes?
Common questions
What makes HEC88473 different from existing GLP-1 drugs?
How long would one injection of HEC88473 last?
Read the original research
First-in-Human Study on Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Escalating Doses of HEC88473, a Novel Dual GLP-1 and FGF21 Receptor Agonist in Healthy and Obese Chinese Subjects.
BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy, 39(3), 477-486
Citation
Zhang, Hong; Li, Qianqian; Chen, Hong; Guo, Lingfeng; Li, Jing; Xie, Can; Yan, Jiangyu; Ding, Yanhua. (2025). First-in-Human Study on Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Escalating Doses of HEC88473, a Novel Dual GLP-1 and FGF21 Receptor Agonist in Healthy and Obese Chinese Subjects.. BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy, 39(3), 477-486. https://doi.org/10.1007/s40259-025-00715-3